Investor Centre

ASX
LCT 0.017   Last updated EOD 12th December 2019
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

Board
Leadership Team
Governance Policies
Dr Bernie Tuch

Dr Bernie Tuch

BSc, MBBS (Hons), FRACP, PhD

Chair, Indep. director

Dr Ken Taylor

Dr Ken Taylor

MPharm, PhD

Executive director

Robert Elliott

Robert Elliott

MBBS, MD, FRACP

Non-executive director

Robert Willcocks

Robert Willcocks

BA, LLM

Independent director

Carolyn Sue

Professor Carolyn Sue AM

MB, BS, PhD, FRACP

Independent Director

Dr Andrew Kelly

Dr Andrew Kelly

BVSc (Hons), MSc, PhD

Independent Director

Elizabeth McGregor

Elizabeth McGregor

MBA, GIA (Cert)

Joint company secretary

Mark Licciardo

Mark Licciardo

B Bus (Acc), GradDip CSP, FGIA, GAICD

Joint company secretary

Dr Tuch is an Honorary Professor at The University of Sydney where he is supervising a bioengineering diabetes cell therapy project.  Previously, he was a senior scientist with CSIRO Australia.  He is a director of Sydney Cell Therapy Foundation Pty Limited, the not-for-profit Australian Foundation for Diabetes Research, and is a Specialist Practitioner, Endocrinology, at the Prince of Wales Private Hospital & St Vincent’s Private Hospital, Sydney. He is also an Adjunct Professor at Monash University.

 

His experience includes capital raising to support his considerable research team and a large international scientific publication list. He has had previous scientific collaborations with LCT and knows the company’s direction intimately.               

 

Dr Tuch is chairman of the Remuneration and Nomination Committee. He was appointed to the board on 20 July 2011 and appointed interim chairman on 31 August 2018.   

Dr Taylor has had a prestigious international career in both academia and business. He completed a postdoctoral fellowship in Pharmacology and Experimental Therapeutics at the Johns Hopkins University School of Medicine in Maryland, USA, and subsequently held a joint appointment in neurosciences at Princeton University and the Squibb Institute of Medical Research in Princeton, New Jersey. He joined Roche Australia and was soon promoted to the role of Medical Director, Australia, before becoming Managing Director of Roche New Zealand. In 1990, Ken was appointed Managing Director of the Roche UK affiliate and then transferred to Syntex in Palo Alto, California to convert the corporate pharmaceutical company to the Roche Bioscience Research Center.

 

Prior to joining LCT, Dr Taylor was CEO of Antipodean Pharmaceuticals where he managed the Phase I and II studies of its lead compound in Parkinson’s disease.

 

New Zealand-born Dr Taylor holds Honours and Doctorate degrees in pharmaceutical chemistry and pharmacology from the University of Otago School of Medicine and completed a business management program at IMD in Lausanne, Switzerland.

 

Ken joined LCT in February 2014 and was appointed to the board on 31 August 2018.

Professor Elliott trained as a paediatrician at Adelaide University. He moved to New Zealand in 1970 to become the Foundation Professor, Director of Paediatrics at The University of Auckland. Professor Elliott co‑founded LCT. He is an Emeritus Professor of Child Health Research and a world leader in diabetes and autoimmune related research. He resigned from the position of Director, Clinical Research and Innovation on 27 February 2015.


In 1999 he was awarded a CNZM (a Companion of the New Zealand Order of Merit) for services to the community. In 2011 he was awarded the prestigious World Class New Zealander (Life Sciences) award.


He is on the board of Cure Kids and patron of the NZ Cystic Fibrosis Foundation. He is a director and shareholder of Breathe Easy Limited, Kopu Limited, Visregen Technologies Limited, Fac8 Limited and NZeno Limited.

           

Professor Elliott resigned as Chairman of the Diatranz Otsuka Limited board of directors in January 2018. He was appointed to LCT board on 15 January 2004.

Robert Willcocks is a senior executive with an extensive legal and business background working in particular with Australian listed public companies. He has Bachelor of Arts and Bachelor of Laws degrees from the Australian National University and a Master of Laws degree from the University of Sydney. Mr Willcocks was a partner with the law firm Stephen Jaques & Stephen (now King & Wood Mallesons) from 1980 until 1994, where he was a member of the Corporate Advisory Group with an emphasis on the mining and oil and gas sectors. As corporate adviser he has undertaken assignments in a range of industry sectors.

 

Mr Willcocks has been a director and Chairman of a number of Australian Securities Exchange (ASX) listed public companies. He is a former director of ASX listed ARC Exploration Limited, and Hong Kong Stock Exchange listed APAC Resources Ltd. He is also chairman and director of Trilogy Funds Management Ltd, a Responsible Entity under Australian law.

 

Mr Willcocks is chairman of the Audit and Compliance Committee and a member of the Remuneration and Nomination Committee.

 

He was appointed to the board on 29 March 2011. 

Dr Sue has an extensive background in neurological science and medicine in relation to chronic illnesses. She is the Head of Neuroscience Research at the Kolling Institute at Sydney’s Royal North Shore Hospital, and Director of Neurogenetics, Director of the National Centre for Adult Stem Cell Research and a Senior Staff Specialist in the Department of Neurology at the Kolling Institute. She holds a M.B., B.S. from the University of New South Wales and a PhD from the University of Sydney and is a Professor at Sydney Medical School. She is also a Fellow of the Royal Australasian College of Physicians (FRACP) and an officer of the Asian-Oceanic Section of the International Movement Disorder Society. 

 

Professor Sue was recognised as a Member in the General Division of the Order of Australia in the 2019 Queen's Birthday honours for her service to medicine.


Professor Sue was appointed to the board on 16 May 2019.

Andrew Kelly has an extensive background in research, commercialisation and investment. In 2005 he co-founded BioPacificVentures, the first specialist venture fund in New Zealand and Australia to focus across the life sciences. In 2014 he broadened the business model to create BioPacific Partners, partnering with some of the largest global companies to invest and engage with local innovation. He has held a dozen board roles over the last 22 years all in businesses involved in life science innovation. Dr Kelly has strong networks across New Zealand and Australia and globally.

 

Dr Kelly spent the early part of his career in life sciences research and development in Australia and Canada and then led research institutes in Australia and New Zealand. He later led product development and then early stage investment at AgResearch. In this role he built deep engagement with the global investor community.

 

Dr Kelly was appointed to the board on 7 November 2019.

Elizabeth is an experienced corporate governance professional. Prior to joining Mertons, she held the position of Governance Manager of the Australian Water Association. Her career includes senior roles with listed and unlisted organisations in healthcare, mining and private equity. Elizabeth was appointed joint company secretary on 30 August 2018.

Mark Licciardo is the founder and managing director of Mertons Corporate Services. He has extensive experience in working with Boards of Directors of high profile ASX listed companies in the areas of corporate governance, accounting & finance and company secretarial practices during a 30 year corporate career in banking and finance, funds management, investment, infrastructure development and in the establishment and management of a consulting business.  A former company secretary of Top 50 ASX listed companies Transurban Group and Australian Foundation Investment Company Limited, Mark is also the former Chairman of the Governance Institute of Australia (GIA) Victoria division and Melbourne Fringe Festival and a current non-executive director of a number of public and private companies.

Dr Ken Taylor

Dr Ken Taylor

MPharm, PhD

Chief Executive

Dr Janice Lam

Dr Janice Lam

PhD

Chief Operating Officer

Daya Uka

Daya Uka

BCom, CA

Chief Financial Officer

Dr Taylor has had a prestigious international career in both academia and business. He completed a postdoctoral fellowship in Pharmacology and Experimental Therapeutics at the Johns Hopkins University School of Medicine in Maryland, USA, and subsequently held a joint appointment in neurosciences at Princeton University and the Squibb Institute of Medical Research in Princeton, New Jersey. He joined Roche Australia and was soon promoted to the role of Medical Director, Australia, before becoming Managing Director of Roche New Zealand. In 1990, Ken was appointed Managing Director of the Roche UK affiliate and then transferred to Syntex in Palo Alto, California to convert the corporate pharmaceutical company to the Roche Bioscience Research Center.

 

Prior to joining LCT, Dr Taylor was CEO of Antipodean Pharmaceuticals where he managed the Phase I and II studies of its lead compound in Parkinson’s disease. 

 

New Zealand-born Dr Taylor holds Honours and Doctorate degrees in pharmaceutical chemistry and pharmacology from the University of Otago School of Medicine and completed a business management program at IMD in Lausanne, Switzerland.

 

Ken joined LCT in February 2014.

Dr Lam oversees all operational aspects of LCT’s business, including operational compliance, the research partnership projects with the University of Auckland and maintaining LCT’s facilities.

 

She has background in biomedical sciences and particular experience in cancer research and pre-clinical animal work.

 

Prior to joining LCT, initially to undertake pre-clinical work for Diabecell, Janice was at Genesis Research and Development.

 

She holds a PhD in Biological Sciences from the University of Auckland.

 

Janice joined LCT in 2010.

Mr Uka has had a varied career working in finance across a range of industries. He joined LCT from Millennium Copthorne Hotels. Daya has a wealth of experience working in ASX- and NZX-listed companies, product commercialisation, cost saving, managing fixed assets, audit as well as mergers and acquisitions. He has held roles at Vector, Pacific Retail Group, Auckland Gas, Carter Holt Harvey, Kmart and Progressive Enterprises.

 

Daya is a member of the Chartered Accountants of New Zealand and Australia and holds a Bachelor of Commerce from the University of Auckland.

 

Daya joined LCT in 2016.

 

Board

Dr Tuch is an Honorary Professor at The University of Sydney where he is supervising a bioengineering diabetes cell therapy project.  Previously, he was a senior scientist with CSIRO Australia.  He is a director of Sydney Cell Therapy Foundation Pty Limited, the not-for-profit Australian Foundation for Diabetes Research, and is a Specialist Practitioner, Endocrinology, at the Prince of Wales Private Hospital & St Vincent’s Private Hospital, Sydney. He is also an Adjunct Professor at Monash University.

 

His experience includes capital raising to support his considerable research team and a large international scientific publication list. He has had previous scientific collaborations with LCT and knows the company’s direction intimately.               

 

Dr Tuch is chairman of the Remuneration and Nomination Committee. He was appointed to the board on 20 July 2011 and appointed interim chairman on 31 August 2018.   

Dr Taylor has had a prestigious international career in both academia and business. He completed a postdoctoral fellowship in Pharmacology and Experimental Therapeutics at the Johns Hopkins University School of Medicine in Maryland, USA, and subsequently held a joint appointment in neurosciences at Princeton University and the Squibb Institute of Medical Research in Princeton, New Jersey. He joined Roche Australia and was soon promoted to the role of Medical Director, Australia, before becoming Managing Director of Roche New Zealand. In 1990, Ken was appointed Managing Director of the Roche UK affiliate and then transferred to Syntex in Palo Alto, California to convert the corporate pharmaceutical company to the Roche Bioscience Research Center.

 

Prior to joining LCT, Dr Taylor was CEO of Antipodean Pharmaceuticals where he managed the Phase I and II studies of its lead compound in Parkinson’s disease.

 

New Zealand-born Dr Taylor holds Honours and Doctorate degrees in pharmaceutical chemistry and pharmacology from the University of Otago School of Medicine and completed a business management program at IMD in Lausanne, Switzerland.

 

Ken joined LCT in February 2014 and was appointed to the board on 31 August 2018.

Professor Elliott trained as a paediatrician at Adelaide University. He moved to New Zealand in 1970 to become the Foundation Professor, Director of Paediatrics at The University of Auckland. Professor Elliott co‑founded LCT. He is an Emeritus Professor of Child Health Research and a world leader in diabetes and autoimmune related research. He resigned from the position of Director, Clinical Research and Innovation on 27 February 2015.


In 1999 he was awarded a CNZM (a Companion of the New Zealand Order of Merit) for services to the community. In 2011 he was awarded the prestigious World Class New Zealander (Life Sciences) award.


He is on the board of Cure Kids and patron of the NZ Cystic Fibrosis Foundation. He is a director and shareholder of Breathe Easy Limited, Kopu Limited, Visregen Technologies Limited, Fac8 Limited and NZeno Limited.

           

Professor Elliott resigned as Chairman of the Diatranz Otsuka Limited board of directors in January 2018. He was appointed to LCT board on 15 January 2004.

Robert Willcocks is a senior executive with an extensive legal and business background working in particular with Australian listed public companies. He has Bachelor of Arts and Bachelor of Laws degrees from the Australian National University and a Master of Laws degree from the University of Sydney. Mr Willcocks was a partner with the law firm Stephen Jaques & Stephen (now King & Wood Mallesons) from 1980 until 1994, where he was a member of the Corporate Advisory Group with an emphasis on the mining and oil and gas sectors. As corporate adviser he has undertaken assignments in a range of industry sectors.

 

Mr Willcocks has been a director and Chairman of a number of Australian Securities Exchange (ASX) listed public companies. He is a former director of ASX listed ARC Exploration Limited, and Hong Kong Stock Exchange listed APAC Resources Ltd. He is also chairman and director of Trilogy Funds Management Ltd, a Responsible Entity under Australian law.

 

Mr Willcocks is chairman of the Audit and Compliance Committee and a member of the Remuneration and Nomination Committee.

 

He was appointed to the board on 29 March 2011. 

Dr Sue has an extensive background in neurological science and medicine in relation to chronic illnesses. She is the Head of Neuroscience Research at the Kolling Institute at Sydney’s Royal North Shore Hospital, and Director of Neurogenetics, Director of the National Centre for Adult Stem Cell Research and a Senior Staff Specialist in the Department of Neurology at the Kolling Institute. She holds a M.B., B.S. from the University of New South Wales and a PhD from the University of Sydney and is a Professor at Sydney Medical School. She is also a Fellow of the Royal Australasian College of Physicians (FRACP) and an officer of the Asian-Oceanic Section of the International Movement Disorder Society. 

 

Professor Sue was recognised as a Member in the General Division of the Order of Australia in the 2019 Queen's Birthday honours for her service to medicine.


Professor Sue was appointed to the board on 16 May 2019.

Andrew Kelly has an extensive background in research, commercialisation and investment. In 2005 he co-founded BioPacificVentures, the first specialist venture fund in New Zealand and Australia to focus across the life sciences. In 2014 he broadened the business model to create BioPacific Partners, partnering with some of the largest global companies to invest and engage with local innovation. He has held a dozen board roles over the last 22 years all in businesses involved in life science innovation. Dr Kelly has strong networks across New Zealand and Australia and globally.

 

Dr Kelly spent the early part of his career in life sciences research and development in Australia and Canada and then led research institutes in Australia and New Zealand. He later led product development and then early stage investment at AgResearch. In this role he built deep engagement with the global investor community.

 

Dr Kelly was appointed to the board on 7 November 2019.

Elizabeth is an experienced corporate governance professional. Prior to joining Mertons, she held the position of Governance Manager of the Australian Water Association. Her career includes senior roles with listed and unlisted organisations in healthcare, mining and private equity. Elizabeth was appointed joint company secretary on 30 August 2018.

Mark Licciardo is the founder and managing director of Mertons Corporate Services. He has extensive experience in working with Boards of Directors of high profile ASX listed companies in the areas of corporate governance, accounting & finance and company secretarial practices during a 30 year corporate career in banking and finance, funds management, investment, infrastructure development and in the establishment and management of a consulting business.  A former company secretary of Top 50 ASX listed companies Transurban Group and Australian Foundation Investment Company Limited, Mark is also the former Chairman of the Governance Institute of Australia (GIA) Victoria division and Melbourne Fringe Festival and a current non-executive director of a number of public and private companies.

Leadership Team

Dr Taylor has had a prestigious international career in both academia and business. He completed a postdoctoral fellowship in Pharmacology and Experimental Therapeutics at the Johns Hopkins University School of Medicine in Maryland, USA, and subsequently held a joint appointment in neurosciences at Princeton University and the Squibb Institute of Medical Research in Princeton, New Jersey. He joined Roche Australia and was soon promoted to the role of Medical Director, Australia, before becoming Managing Director of Roche New Zealand. In 1990, Ken was appointed Managing Director of the Roche UK affiliate and then transferred to Syntex in Palo Alto, California to convert the corporate pharmaceutical company to the Roche Bioscience Research Center.

 

Prior to joining LCT, Dr Taylor was CEO of Antipodean Pharmaceuticals where he managed the Phase I and II studies of its lead compound in Parkinson’s disease. 

 

New Zealand-born Dr Taylor holds Honours and Doctorate degrees in pharmaceutical chemistry and pharmacology from the University of Otago School of Medicine and completed a business management program at IMD in Lausanne, Switzerland.

 

Ken joined LCT in February 2014.

Dr Lam oversees all operational aspects of LCT’s business, including operational compliance, the research partnership projects with the University of Auckland and maintaining LCT’s facilities.

 

She has background in biomedical sciences and particular experience in cancer research and pre-clinical animal work.

 

Prior to joining LCT, initially to undertake pre-clinical work for Diabecell, Janice was at Genesis Research and Development.

 

She holds a PhD in Biological Sciences from the University of Auckland.

 

Janice joined LCT in 2010.

Mr Uka has had a varied career working in finance across a range of industries. He joined LCT from Millennium Copthorne Hotels. Daya has a wealth of experience working in ASX- and NZX-listed companies, product commercialisation, cost saving, managing fixed assets, audit as well as mergers and acquisitions. He has held roles at Vector, Pacific Retail Group, Auckland Gas, Carter Holt Harvey, Kmart and Progressive Enterprises.

 

Daya is a member of the Chartered Accountants of New Zealand and Australia and holds a Bachelor of Commerce from the University of Auckland.

 

Daya joined LCT in 2016.

 

Governance Policies
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.